Lantern Pharma Inc.
Lantern Pharma Inc. is a clinical-stage biopharmaceutical company focused on using its RADR® AI/ML platform to discover and develop oncology drug candidates. It combines de novo biomarker-guided programs with a “rescue” strategy for previously studied compounds that may be repurposed for more targeted cancer trials.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDrug candidates in preclinical and clinical development for cancer indications.
RADR® and related machine-learning tools used to identify and de-risk candidates.
Previously studied compounds being re-evaluated with biomarker and AI methods.
Customers
Lantern Pharma does not sell commercial medicines today; its primary “customers” are investors, research partners, and future licensing or commercialization partners that support development of its pipeline. In the longer term, the end customers would be oncology patients and the physicians and hospitals treating them, if any candidate reaches approval. The company also seeks grant funding and may pursue collaborations to help finance development.
Equity investors and other financiers fund the company because it has no product revenue and needs capital for development.
Pharma or biotech partners may license, co-develop, or acquire programs to share development risk and access the RADR® platform.
Public or private grant funders may support specific research or translational work to extend runway.
If approved, hospitals, physicians, and patients would use the therapies for biomarker-guided cancer treatment.
Strategy
The company’s strategy is to build an oncology pipeline using RADR® and other machine-learning methods, while also identifying historical drug candidates that can be revived with better biomarker selection and more targeted trials. Management is focused on advancing LP-300, LP-184, and LP-284, expanding the platform, and preserving enough capital to keep development moving toward regulatory approval. The strategy is designed to reduce clinical risk and improve the odds of finding the right patient for the right therapy.
Clinical progress is the main value driver because the company currently has no product revenue.
RADR® and biomarker-guided selection are intended to improve trial success rates and reduce wasted spend.
The company expects substantial future funding needs to support trials and operations.
Geography
Lantern Pharma is headquartered in the United States and reports no product revenue to date. Its development work is global in scope, with the company specifically noting clinical testing activity in Taiwan for LP-300, which creates geographic execution and geopolitical exposure. The business is still largely U.S.-financed, but trial operations and future commercialization could extend into additional markets.
Risks
Lantern Pharma is a pre-revenue biotech, so its business depends on successful clinical development, regulatory approval, and access to external capital. The company also faces execution risk from trial enrollment, manufacturing, competition, and the possibility that its AI-driven approach does not translate into approved therapies. Geographic exposure, including Taiwan-based clinical work, adds geopolitical and operational uncertainty.
LP-300, LP-184, LP-284 and other programs may not show sufficient efficacy or safety to advance.
Exposure: Lead pipeline programs
The company expects substantial additional funding needs and may need to raise equity on unfavorable terms.
Exposure: Operating runway and ownership dilution
Even if candidates succeed clinically, the company must still build manufacturing, sales, and distribution capabilities.
Exposure: Future launch readiness
Management explicitly cited Taiwan as a location for clinical testing, which can affect timelines and operations.
Exposure: Clinical operations
Accounting
Judgemental itemsThe company currently has no product revenue, so any future license or grant revenue will be important and likely uneven.
Impact: Reported revenue may remain minimal until a partnership or approval occurs.
Clinical and preclinical spending varies by program and quarter, making operating losses volatile.
Impact: Quarterly results may not be directly comparable across periods.
The company has historically financed operations through equity sales and may continue to do so.
Impact: Share count and per-share metrics can change materially.
Management states it will need substantial additional funding to continue development.
Impact: Runway and financing assumptions are central to valuation.
Similar listed companies
Publicly listed companies with a comparable business focus.
LadRx Corp
Biological Products, (No Diagnostic Substances)
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development.
LB Pharmaceuticals Inc
LBRX · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Lantheus Holdings, Inc.
LNTH · In Vitro & In Vivo Diagnostic Substances
Erasca, Inc.
ERAS · Pharmaceutical Preparations
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
Last updated: 24/09/2026